1. Melphalan pivotal PIII trial going well, will be completed this year. Could be on market in 2014 or early 2015. LGND has received interest from potential partners, will make a decision on whether to go alone with distribution or partner.
2. Alzheimer's drug licensed to MRK generating a lot of excitement. Going into PII trial with option of extension into PIII. By biomarker assay, the efficacy of the drug looks robust. MRK highlighted this Alz drug in their recent cc.
3. Higgins affirmed that Promacta is a billion+ drug. Trials in cancer indications going well. GSK has a top team working on expanding indications and global reach for Pro, and the revenue growth has been very solid with a 70% year-over-year growth.
4. There are 6 partnered drugs that could receive FDA approval and start marketing in the next 3 years.
Increasing arsenal of approved and partnered drugs, increasing royalties and revenues- sit back and enjoy the ride!